Abstract
Introduction
Pancreatic cancer is estimated to be the third leading cause of cancer-related mortality in the United States (US). 1, 2 As has been the case for many years, the projected number of deaths in 2019 (45, 750 ) is expected to nearly equal the number of new cases (56, 770) . 1, 2 While the 5-year survival rate for all stages combined is approximately 9% (lowest among all cancers), more than half of all patients diagnosed with pancreatic cancer present with metastatic disease, which carries a 5-year survival rate of approximately 3%. 1, 2 Prior to recent treatment advances, single-agent gemcitabine was the standard of care for many years for patients with metastatic pancreatic cancer (mPC). 3 Today, gemcitabine monotherapy remains a therapeutic option for patients with mPC who have poor performance status, 4, 5 but for patients with good performance status, it has been shown to be inferior compared with two newer chemotherapy combinations. In the PRODIGE/ACCORD trial of patients with mPC, treatment with FOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, and irinotecan) resulted in a median overall survival (OS) of 11.1 months versus 6.8 months with gemcitabine alone [hazard ratio (HR), 0.57; 95% confidence interval (CI), 0.45-0.73; p < 0.001]. 6 The MPACT trial randomized patients with mPC to treatment with nab-paclitaxel plus gemcitabine (nab-P/G) or gemcitabine alone; the median OS with nab-P/G was 8.7 months versus 6.6 months with gemcitabine alone (HR, 0.72; 95% CI, 0.62-0.83; p < 0.001). 7, 8 Of note, the PRODIGE/ACCORD trial enrolled a higher percentage of patients with good performance status [Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 in 38.0%, 1 in 61.7%, and 2 in 0.3% of patients] compared with the MPACT trial [Karnofsky performance status of 100 (equivalent to ECOG PS of 0) in 16%, 90/80 (equivalent to ECOG PS of 1) in 76%, and 70/60 (equivalent to ECOG PS of 2) in 8% of patients]. 6, 7, 9 In a recent phase II study assessing nab-P/G specifically in patients with poor performance status (ECOG PS of 2), the median OS in patients with advanced disease who received treatment at the same dose and schedule as in the MPACT trial was 8.7 months. 10 On the basis of these results, the current National Comprehensive Cancer Network and European Society for Medical Oncology guidelines recommend combination chemotherapy with nab-P/G or FOLFIRINOX as the preferred first-line treatments for patients with mPC who have good performance status. 4, 5 A recent study assessing the patterns and predictors of systemic therapy choices in mPC reported that the use of first-line gemcitabine monotherapy in the US decreased from 72% in 2006 to 16% in 2015. Conversely, there was a reciprocal increase in the use of either nab-P/G or FOLFIRINOX in this setting. 11 This study also found that patients treated at community practices and by oncologists with lower volumes of patients with mPC were more likely to receive nab-P/G as a first-line treatment, while younger male patients were more likely to receive FOLFIRINOX. 11 However, the rationale for choosing between nab-P/G and FOLFIRINOX remains unclear.
To date, there has been no head-to-head randomized, controlled trial comparing nab-P/G with FOLFIRINOX in patients with mPC. Therefore, a number of retrospective, nonrandomized studies from institutional or healthcare systems have compared nab-P/G and FOLFIRINOX in an attempt to elucidate differences in safety and effectiveness. However, cross-comparisons between trials are not ideal; for example, the numerically higher OS observed with FOLFIRINOX in PRODIGE/ ACCORD 6 versus nab-P/G in MPACT 7 could lead physicians to believe that FOLFIRINOX has improved effectiveness. A recent systematic review of clinical trial data attempted to fill this gap. 12 The study reported that several combination chemotherapies, including nab-P/G and FOLFIRINOX, were associated with significant improvement in survival compared with gemcitabine alone, but there were no significant differences between nab-P/G and FOLFIRINOX in terms of OS and progression-free survival (PFS). 12 Furthermore, the available clinical trial data did not allow for a reliable assessment of differences in resource utilization, duration of treatment, or treatment costs. Given the lack of clinical trial data directly comparing the two regimens, there remains a need to assess the currently available real-world data to determine whether differences in outcomes exist between nab-P/G and FOLFIRINOX.
To address this need, we conducted a systematic review of real-world patient data comparing outcomes, including effectiveness, safety, duration of treatment, supportive care use, and resource utilization, with nab-P/G versus FOLFIRINOX as a first-line therapy in patients with advanced pancreatic cancer (aPC) which includes mPC. Our hope is that these results will facilitate more informed treatment decisions in this patient population.
Methods

Search strategy
The Embase and MEDLINE databases were searched through 22 January 2019, with no limit for the start date. In addition, the American Society of Clinical Oncology Meeting Library was searched for studies presented at the 2019 Gastrointestinal Cancers Symposium that were not yet indexed in the searched databases. Studies were included in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement. The search was limited to publications in English, and the search terms, including nab-P/G and FOLFIRINOX, were designed to ensure full coverage of the relevant journals.sagepub.com/home/tam 3 patient populations, interventions, study designs, and outcomes (Appendix A).
Eligibility criteria
Abstracts were separately screened by two independent reviewers and any discrepancies were resolved through discussion and consensus. Studies included were real-world, retrospective analyses of first-line therapy in patients with mPC or aPC that directly compared nab-P/G with FOLFIRINOX. Eligible studies were required to have data on effectiveness [OS, PFS, time to treatment failure (TTF), or overall response rate (ORR)], treatment duration, or resource utilization. Studies with radiotherapy and review articles were excluded, and duplicates were removed.
Data extraction and reporting
Selected studies were reviewed and data on populations, interventions, and outcomes were extracted from abstracts, posters, and full papers into a database. Data included region, treatment period, number of patients (total and in each arm), baseline and clinical characteristics (including ECOG PS), effectiveness and safety outcomes, treatment duration, cost of therapy, resource utilization, and second-line treatment, including any associated outcomes. The quality of the included studies was independently assessed by two reviewers using the NewcastleOttawa Scale (NOS). 13 Any disagreements were resolved by a third reviewer. The NOS was developed to assess the quality of nonrandomized casecontrol and cohort studies based on three parameters, selection, comparability, and exposure/outcome, and assigns a maximum of 4, 2, and 3 stars, respectively, for these domains. A study was considered as high quality if the NOS score was ⩾7 stars. 14, 15 Because some studies did not report patient numbers, the values reported in this review are noted as being greater than the sum of the patient numbers reported in each particular category. In addition, the data reported varied by study (e.g. decimals/no decimals); we chose to represent all values as they appeared in the original reports for accuracy.
Results
Study selection
The initial search identified 818 records, of which 35 were duplicates; an additional 749 were excluded based on eligibility criteria, leaving 34 studies for further analysis (Figure 1 ). In general, patients who received nab-P/G were older and had worse performance status than those who received FOLFIRINOX. Age was reported separately for the two groups in 21 studies, and the median/mean age of patients who received nab-P/G was numerically greater than those who received FOLFIRINOX (Table 1 ). In 11 of the 17 studies that reported ECOG PS separately for the two groups, a higher proportion of patients had good performance status (ECOG PS of 0 or 1) in the FOLFIRINOX cohort; 5 studies had equal proportions, and 1 had a higher proportion of patients with good performance status in the nab-P/G group (Table 1 ).
Study and population characteristics
Of the 32 included studies, 23 (72%) were assessed by the NOS to be of high quality (⩾7 stars; Supplementary Table 1) . The remaining nine studies were of moderate quality (seven studies with 6 stars; two studies with 5 stars), primarily due to comparability and outcome biases. The mean NOS score across all studies was 7.47. The most common comparability bias was the absence of study-controlled factors in addition to the compared patient population. The most common outcome bias was the lack of reporting of adequate follow up. Several studies did not receive an NOS star for selection and outcome parameters because they did not report a specific record or database used to ascertain exposures or assess outcomes.
Effectiveness outcomes
Overall, 31 studies (>5237 patients) reported an OS, PFS, or TTF ( Table 2 ). Among the 30 direct comparisons, a numerically longer median OS was reported with FOLFIRINOX in 18 versus 9 with nab-P/G; 3 studies reported equal median OS values between the two groups. All reported median OS values for the two groups are shown in Figure 2 . A statistical comparison (p value) of OS between the nab-P/G and FOLFIRINOX groups was reported in 13 studies (14 p values). No statistically significant difference in OS between the two groups (as judged by p > 0.05) was reported in 12 of the 14 comparisons; 1 study each reported significantly greater OS with nab-P/G (p = 0.002) and FOLFIRINOX (p = 0.02; Table 2 ). In two studies that also reported OS in patients with good performance status (ECOG PS 0 or 1), the median OS in patients with ECOG PS 0 or 1 treated with nab-P/G versus FOLFIRINOX were 12.1 versus 11.4 months and 14.1 versus 13.7 months, respectively. 27, 30 Among the 18 direct comparisons (10 in patients with mPC and 8 in those with aPC; >2388 patients), the median PFS was numerically longer with FOLFIRINOX in 10 studies versus 7 studies with nab-P/G; in 1 study, the median PFS for the nab-P/G group was not reached. The TTF or time to discontinuation was reported in four mPC studies (1511 patients), with numerically longer TTF in three studies with FOLFIRINOX versus one study with nab-P/G (Table 2) .
Overall, six studies reported response data. In two studies that reported response data for patients with mPC, the ORRs were 34% and 39% with nab-P/G versus 34% (p = 0.88) and 27% (p = 0.02), respectively, with FOLFIRINOX. 25, 29 In four studies that reported response data for patients with aPC, the ORR was greater with nab-P/G or with FOLFIRINOX in two studies each. 37, 39, 46, 47 A total of six studies reported disease control rates (DCRs; three each in mPC and aPC). In five of these studies, the DCR was numerically greater with nab-P/G. 25, 29, 37, 39, 46 Overall, one study (patients with mPC) reported numerically greater DCR with FOLFIRINOX. 19
aPC, advanced pancreatic cancer; FFX, FOLFIRINOX; mPC, metastatic pancreatic cancer; nab-P/G, nab-paclitaxel/ gemcitabine. a Studies could be excluded for ⩾1 reason; once 1 reason was identified, no attempt was made to look for other potential reasons. b Includes abstracts for which full manuscripts were subsequently published, encore presentations (most recent presentation included), or abstracts that were presented with updated data later. c The symbol > indicates that some studies did not report the number of patients treated with nab-P/G or FFX and others evaluated additional treatment regimens. d The symbol > indicates that some studies did not report the number of patients with mPC. Second-line chemotherapy A total of 10 studies (2184 patients) reported data on the proportion of patients who received second-line chemotherapy. In nine studies that reported data separately for the two regimens, 9-76% of patients treated with nab-P/G as firstline therapy received second-line therapy versus 9-94% of those treated with FOLFIRINOX as first-line therapy. 11, 17, 19, 26, 29, 39, 40, 42, 46 Overall, one study reported that 44% of patients received second-line chemotherapy. 33 Only two of these studies reported OS data in patients receiving second-line therapy. One study reported a median OS of 18 months in 6 patients treated with firstline nab-P/G and second-line FOLFIRINOX and 10.8 months in 20 patients treated with first-line FOLFIRINOX and second-line nab-P/G. 19 The other study reported second-line median OS of 4.8 months in patients treated with first-line nab-P/G and second-line fluorouracil (alone or with oxaliplatin; 96% of patients) and 4.5 months in patients treated with first-line FOLFIRINOX and a second-line gemcitabine-based regimen (97% of patients). 29 
Safety outcomes
Safety outcomes were reported in 14 studies (2205 patients), including 8 single-institution studies. The incidence of all grade and grade 3/4 adverse events (AEs) is summarized in Table 3 . Among the six single-institution studies to report grade 3/4 neutropenia, the rates were higher with FOLFIRINOX in five studies versus one study with nab-P/G. Among the seven single-institution studies to report grade 3/4 peripheral neuropathy, the rates were higher in one study with FOLFIRINOX versus four with nab-P/G; identical rates were reported in two studies. The incidence of grade 3/4 febrile neutropenia was higher with FOLFIRINOX in all three single-institution studies that reported this AE. In the two single-institution studies that reported discontinuation rates, a numerically greater percentage of patients treated with FOLFIRINOX discontinued due to AEs versus those treated with nab-P/G.
Supportive care/resource utilization
A total of five studies (1986 patients) reported data on supportive care or resource utilization. 18, 20, 22, 25, 27 In two studies (605 patients) that reported frequency of granulocyte colony-stimulating factor (G-CSF) use, fewer patients treated with nab-P/G received G-CSF (0% and 27%) versus those treated with FOLFIRINOX (21% and 55%, respectively). 18, 25 Overall, one study reported that patients treated with nab-P/G received fewer doses mOS, median overall survival; n, number of studies reporting mOS; nab-P/G, nab-paclitaxel/gemcitabine. of G-CSF (2.02 per 100 days) and more doses of steroids (7.89 per 100 days) and erythropoiesisstimulating agents (0.9 per 100 days) versus those treated with FOLFIRINOX (4.41, 5.79, and 0.13 doses per 100 days, respectively). 20 A study (486 patients) reported that significantly fewer patients treated with nab-P/G received pegfilgrastim (13%) versus those treated with FOLFIRINOX (43%); the use of darbepoetin, antibiotics, pain medications, or medications for treating chemotherapyinduced nausea/vomiting was similar in the two groups. 27 A study (345 patients) reported that hospitalization rates were significantly lower in patients treated with nab-P/G (24.7%) versus those treated with FOLFIRINOX (36.8%; p = 0.027), and hospital stays were significantly shorter with nab-P/G (1.7 days) versus FOLFIRINOX (3.6 days; p = 0.002). 22 Cost of care A total of four studies (1532 patients) reported data on costs associated with healthcare in patients treated with nab-P/G and FOLFIRINOX. 18, 22, 24, 28 Overall, two studies reported that the total monthly cost of care for patients treated with nab-P/G was US$16,628 and US$23,605 versus US$19,936 and US$26,575, respectively, for those treated with FOLFIRINOX. 22, 24 Monthly costs related to chemotherapy ranged from US$11,662 to US$12,103 for patients treated with nab-P/G and US$6384 to US$9564 for those treated with FOLFIRINOX, while those for supportive care ranged from US$1836 to US$2966 and US$3955 to US$8758, respectively. 18, 22, 24 The majority of the supportive care cost was the cost of G-CSF, which ranged from US$917 to US$1005 and US$3214 to US$5459 per month, respectively. 18, 22, 24 A study reported that the costs for patients treated with nab-P/G were lower for filgrastim (US$234), pegfilgrastim (US$759), and drug administration (US$1859) versus those treated with FOLFIRINOX (US$529, US$4860, and US$2969, respectively). 24 Another study reported that the costs for erythropoietin, transfusions, and antiemetics were similar for the two regimens, but no individual values were reported. 18 Another study that did not provide specific data noted that the cost of anticancer therapy was similar in the two groups, but the total cost of treatment was slightly lower in the nab-P/G group. 28 
Discussion
This systematic review reports data from 34 studies that assessed first-line treatment in a real-world setting of 16,505 patients, including at least 6349 patients with mPC who were treated with nab-P/G or FOLFIRINOX (see Table 1 ). Although the effectiveness of nab-P/G and FOLFIRINOX in patients with mPC or aPC varied among studies, most of the survival data tended to overlap (see Table 2 and Figure 2) . Furthermore, in 12 of 14 statistical comparisons, the OS was not significantly different between patients treated with nab-P/G versus FOLFIRINOX. Overall, these data suggest that first-line nab-P/G and FOLFIRINOX have similar effectiveness in patients with aPC in the real-world setting.
In most studies reporting safety, the authors concluded that nab-P/G exhibited a more favorable safety profile than FOLFIRINOX. Some studies reported that patients treated with nab-P/G experienced fewer and less severe AEs, needed dose modifications less frequently, and discontinued less often because of AEs. In real-world studies, comparing safety data, especially nonlaboratory-based AEs, is problematic due to the lack of uniform definitions as used in randomized clinical trials; therefore, we focused on comparing grade 3/4 AEs reported for the two regimens within single-institutional studies.
In most of these studies, the rates were higher with FOLFIRINOX versus nab-P/G for grade 3/4 neutropenia (five of six studies) and febrile neutropenia (three of three studies). Consistent with this, a numerically greater proportion of patients discontinued FOLFIRINOX treatment due to AEs in two studies. In contrast, the rates of grade 3/4 peripheral neuropathy were higher with nab-P/G versus FOLFIRINOX in most (four of seven) single-institutional studies. However, in the MPACT trial, grade ⩾3 neuropathy associated with nab-P/G was reported to improve to grade ⩽1 in a median of 29 days. 7 Studies reporting supportive care, resource utilization, and cost data were limited but provided some insight into the differences between regimens, such as lower use of G-CSF with nab-P/G. Monthly costs of chemotherapy were higher with nab-P/G, but the overall monthly cost ranges were higher with FOLFIRINOX. Additional options, such as use of biosimilar G-CSF, may help reduce the overall cost associated with FOLFIRINOX treatment.
In 2014, Gresham and colleagues performed a systematic review and network meta-analysis of randomized clinical trials of chemotherapy regimens in patients with aPC (9989 patients in 23 studies) that included nab-P/G and FOLFIRINOX. 12 Our observation that there was no clear distinction in effectiveness between nab-P/G and FOLFIRINOX journals.sagepub.com/home/tam 13 is consistent with their report of no significant difference in OS or PFS between the two regimens. In direct comparisons, FOLFIRINOX was associated with significantly higher odds of grade 3/4 neutropenia versus nab-P/G, whereas no statistically significant difference was noted between the two regimens in the odds ratios for grade 3/4 sensory neuropathy, fatigue, diarrhea, or febrile neutropenia. 12 In the PRODIGE/ACCORD trial, the most common grade 3/4 AEs with FOLFIRINOX were neutropenia (46%), fatigue (24%), vomiting (15%), diarrhea (13%), thrombocytopenia (9%), sensory neuropathy (9%), anemia (8%), thromboembolism (7%), and febrile neutropenia (5%). 6 In the MPACT study, the most common grade ⩾3 AEs with nab-P/G were neutropenia (38%), fatigue (17%), peripheral neuropathy (17%), thrombocytopenia (13%), anemia (13%), diarrhea (6%), and febrile neutropenia (3%). 7 Post hoc analyses of the MPACT trial also demonstrated that nab-P/G dose reductions and dose delays are additional strategies that can help reduce toxicity without compromising efficacy, and that prolonged firstline treatment with nab-P/G until disease progression can improve survival rates. 49, 50 Similarly, various modifications in FOLFIRINOX components and doses are often experimented with in clinical practice in efforts to improve outcomes.
The recent results from the PRODIGE 24-ACCORD trial showed significantly longer disease-free survival and OS in patients receiving a modified FOLFIRINOX regimen (without bolus fluorouracil) compared with those receiving gemcitabine in the adjuvant setting. 51 The most common grade 3/4 AEs reported with the modified FOLFIRINOX regimen were neutropenia (28%), diarrhea (19%), increased γ-glutamyltransferase levels (18%), paresthesia (13%), fatigue (11%), sensory peripheral neuropathy (9%), nausea (5%), and vomiting (5%). 51 These results may support tolerability of modified FOLFIRINOX in the adjuvant setting and suggest the potential for use in patients with mPC. The National Comprehensive Cancer Network guidelines were revised recently to include modified FOLFIRINOX as a preferred category 1 recommendation for mPC. 5 The results from the MPACT and PRODIGE trials brought meaningful promise to the treatment landscape for patients with mPC; therefore, the focus now is centered on determining the optimal sequence of these regimens. As a result of the phase III NAPOLI-1 trial, liposomal irinotecan plus fluorouracil and leucovorin is a National Comprehensive Cancer Network category 1 recommendation for patients who received first-line gemcitabine-based therapy. 5, 52, 53 Further, several early-stage clinical trials have investigated the sequencing of nab-P and fluorouracil-based regimens. In GABRINOX, a phase I/II study that assessed treatment with nab-P/G followed by FOLFIRINOX in patients with mPC, a median OS of 17.8 months was reported. 54 However, this regimen resulted in grade 3/4 neutropenia, thrombocytopenia, and diarrhea occurring at higher frequencies compared with nab-P/G or FOLFIRINOX alone. 6, 7 In SEENA-1, a phase II study of nab-P/G followed by either modified FOLFIRINOX (without bolus fluorouracil) or nab-P/G alternating with FOLFIRI (without oxaliplatin), a median OS of 12.3 months and a safety profile generally similar to that for nab-P/G or FOLFIRINOX alone were reported. 6, 7, 55 A phase II study recently showed that using FOLFIRINOX in a stop-and-go fashion (4-month FOLFIRINOX followed by LV5FU2 maintenance) produced similar efficacy (PFS, 5.7 months; OS, 11.2 months) compared with 6-month FOLFIRINOX (PFS, 6.3 months; OS, 10.1 months). 56 However, this strategy resulted in a greater proportion of patients with grade 3/4 neurotoxicity (19%) compared with standard FOLFIRINOX (10%). Finally, multiple algorithms have been proposed to guide treatment decisions in individual cases. 57, 58 Future efforts may shed additional light on appropriate sequencing regimens for personalized care.
Study limitations
The sample size of 34 studies may be considered relatively small, and this may impact the ability to draw strong conclusions from the data. In addition, in the absence of standardizing criteria used in randomized clinical trials, interpretation of certain outcomes (e.g. response data) is problematic with real-world evidence from multi-institutional studies. Furthermore, the studies varied in terms of population, treatment duration, study design, and details of specific results. Some of the differences in patient characteristics may also have affected the observed outcomes. For example, healthier/younger patients treated more frequently with FOLFIRINOX versus nab-P/G may have confounded the results in some studies. 17, 23, 26, 27, 31, 37, 40 Finally, although data regarding cost have been presented, few studies report this type of information, and it is typically difficult to standardize or quantify.
In addition, studies of patients with aPC were included to maximize the inclusion of patients with mPC. The OS, a more reliable indicator of effectiveness than other measures, was reported in only approximately 50% of the patients treated with nab-P/G or FOLFIRINOX. To date, data from most of the included studies were not completely mature, and some studies did not report patient numbers, which may have added to the variability and lower quality of some studies caused by a reporting bias. Overall, the variability did not allow for performance of a robust metaanalysis with specific comparisons of effectiveness and safety outcomes.
Conclusion
To our knowledge, this is the first systematic review examining real-world outcomes with nab-P/G versus FOLFIRINOX as first-line therapy in patients with aPC or mPC. In the absence of a direct comparison in a head-to-head clinical trial of first-line therapy in patients with mPC, this systematic review may help highlight differences between the two regimens to assist with clinical decision making. While this report has limitations inherent to systematic reviews, it included a large number of patients, and a comparison of the real-world data with the published clinical trial data allowed for overarching conclusions with respect to outcomes. The variability of data in the current literature makes it difficult to directly compare the two standard first-line regimens for mPC. Although FOLFIRINOX was associated with slightly longer median OS in more studies, the differences, when available, were not statistically significant. Furthermore, FOLFIRINOX was associated with more treatment-related toxicities. Individual patient considerations, goals of care, and future molecular marker-driven clinical trials may improve patient-physician decision on selecting the best sequence of anticancer therapy for mPC.
